11 – 15 February 2017 Wed, 15 February
Davos 2
08:00 – 09:30 Session 1: Aortic Valve Disease
Chairs: U. Landmesser, Berlin and T. F. Lüscher, Zurich
08:00 The role of imaging in aortic valve disease F. J. Pinto, Lisbon
08:22 TAVI: from high risk patients to first line therapy? F. Nietlispach, Zurich
08:44 Optimal antithrombotic treatment during and after TAVI S. Windecker, Berne
09:06 TAVI after bioprosthetic failure A. Vahanian, Paris
Davos 2
09:30 – 09:45 Poster Award

09:45 – 10:00 Coffee

Davos 2
10:00 – 11:30 Session 2: Heart Failure
Chairs: B. Pitt, Ann Arbor and K. B. Swedberg, Gothenburg
10:00 Chronic heart failure P. Ponikowski, Wroclaw
10:22 Comorbidities in heart failure S. D. Anker, Göttingen
10:44 Devices and interventions F. Ruschitzka, Zurich
11:06 Acute heart failure G. Filippatos, Athens
Davos 2
12:00 – 13:15 Lunch / Satellite Symposium Vifor Pharma (a lunch bag will be offered)
Chair: B. Pitt, Ann Arbor

How too much or too little may affect our heart

12:00 Introduction B. Pitt, Ann Arbor
12:05 Should iron be at the heart of the concerns? P. Ponikowski, Wroclaw
12:35 Potassium: Friend or foe? S. D. Anker, Göttingen
13:05 Discussion and take-home message B. Pitt, Ann Arbor
Davos 2
13:30 – 15:00 Session 3: Heart Failure
Chairs: S. D. Anker, Göttingen and G. Filippatos, Athens
13:30 Heart failure randomized clinical trials: looking back – looking forward M. A. Pfeffer, Boston
13:52 Heart failure with preserved systolic function S. D. Solomon, Boston
14:14 Which patients with chronic HF should change treatment from an ACE-inhibitor to sacubitril/valsartan? K. B. Swedberg, Gothenburg
14:36 New directions in HF treatment B. Pitt, Ann Arbor
15:00 – 15:15 Coffee

Schwarzhorn
15:15 – 16:15 Meet the Expert Session: Zurich / Oslo Interactive Cases
Moderators: O. A. Smiseth, Oslo and F. Enseleit, Zurich

Heart failure and valve disease

15:15 Clinical case 1: A patient with heart failure and mitral regurgitation J. Aalen, Oslo
15:30 What do the guidelines say? O. A. Smiseth, Oslo
15:40 Clinical case 2: A patient with heart failure and aortic stenosis S. Stämpfli, Zurich
15:55 What do the guidelines say? F. Enseleit, Zurich
16:05 Panel discussion and questions from the audience
Seehorn
15:15 – 16:15 Meet the Expert Session: Zurich / Zagreb Interactive Cases
Moderators: A. Flammer, Zurich and M. Cikes, Zagreb

Chronic and advanced heart failure

15:15 Clinical case 1: A patient with chronic heart failure I. Planinc, Zagreb
15:30 What do the guidelines say? M. Cikes, Zagreb
15:40 Clinical case 2: A patient with advanced heart failure S. Winnik, Zurich
15:55 What do the guidelines say? A. Flammer, Zurich
16:05 Panel discussion and questions from the audience
Davos 2
16:15 – 17:15 Session 4: Advanced Heart Failure and Stem Cells
Chairs: L. Lund, Stockholm and S. D. Solomon, Boston
16:15 LVAD: bridge to transplantation or destination therapy? G. Gerosa, Padova
16:35 Heart transplantation – still a golden standard for the end stage heart failure? D. Milicic, Zagreb
16:55 Stem cells in HF U. Landmesser, Berlin
Davos 2
17:15 – 17:30 Closing Address by the ESC President
J. J. Bax, Leiden
Davos 2
17:30 – 17:45 Adjourn
B. Pitt, Ann Arbor and T. F. Lüscher, Zurich